Severe hemophilia A caused by an unbalanced chromosomal rearrangement identified using nanopore sequencing.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
07 2019
Historique:
received: 14 03 2019
accepted: 18 04 2019
pubmed: 26 4 2019
medline: 15 7 2020
entrez: 26 4 2019
Statut: ppublish

Résumé

Essentials No F8 genetic abnormality is detected in about 2% of severe hemophilia A patients. Detection of F8 structural variants remains a challenge. We identified a new F8 rearrangement in a severe hemophilia A patient using nanopore sequencing. We highlight the value of single-molecule long-read sequencing technologies in a genomics laboratory. No F8 genetic abnormality is detected in about 2% of severe hemophilia A patients using conventional genetic approaches. In these patients, deep intronic variation or F8 disrupting genomic rearrangement could be causal. To characterize, in a genetically unresolved severe hemophilia A patient, a new Xq28 rearrangement disrupting F8 using comprehensive molecular techniques including nanopore sequencing. Long-range polymerase chain reaction (PCR) performed throughout F8 identified a nonamplifiable region in intron 25 indicating the presence of a genomic rearrangement. F8 messanger ribonucleic acid (mRNA) analysis including 3'rapid amplification of complementary deoxyribonucleic acid (cDNA) ends and nanopore sequencing found the presence of a F8 fusion transcript in which F8 exon 26 was replaced by a 742-bp pseudoexon corresponding to a noncoding region located at the beginning of the long arm of chromosome X (Xq12; chrX: 66 310 352-66 311 093, GRCh37/hg19). Cytogenetic microarray analysis found the presence of a Xq11.1q12 gain of 3.8 Mb. The PCR amplification of junction fragments and fluorescent in situ hybridization (FISH) analysis found that the Xq11q12 duplicated region was inserted in the F8 intron 25 genomic region. We characterized a novel genomic rearrangement in which a 3.8-Mb Xq11.1q12 gain inserted in the F8 intron 25 led to an aberrant fusion transcript in a patient with severe hemophilia A (HA), using comprehensive molecular techniques. This study highlights the value of single-molecule long-read sequencing technologies for molecular diagnosis of HA especially when conventional genetic approaches have failed.

Sections du résumé

Essentials No F8 genetic abnormality is detected in about 2% of severe hemophilia A patients. Detection of F8 structural variants remains a challenge. We identified a new F8 rearrangement in a severe hemophilia A patient using nanopore sequencing. We highlight the value of single-molecule long-read sequencing technologies in a genomics laboratory.
BACKGROUND
No F8 genetic abnormality is detected in about 2% of severe hemophilia A patients using conventional genetic approaches. In these patients, deep intronic variation or F8 disrupting genomic rearrangement could be causal.
OBJECTIVE
To characterize, in a genetically unresolved severe hemophilia A patient, a new Xq28 rearrangement disrupting F8 using comprehensive molecular techniques including nanopore sequencing.
RESULTS
Long-range polymerase chain reaction (PCR) performed throughout F8 identified a nonamplifiable region in intron 25 indicating the presence of a genomic rearrangement. F8 messanger ribonucleic acid (mRNA) analysis including 3'rapid amplification of complementary deoxyribonucleic acid (cDNA) ends and nanopore sequencing found the presence of a F8 fusion transcript in which F8 exon 26 was replaced by a 742-bp pseudoexon corresponding to a noncoding region located at the beginning of the long arm of chromosome X (Xq12; chrX: 66 310 352-66 311 093, GRCh37/hg19). Cytogenetic microarray analysis found the presence of a Xq11.1q12 gain of 3.8 Mb. The PCR amplification of junction fragments and fluorescent in situ hybridization (FISH) analysis found that the Xq11q12 duplicated region was inserted in the F8 intron 25 genomic region.
CONCLUSION
We characterized a novel genomic rearrangement in which a 3.8-Mb Xq11.1q12 gain inserted in the F8 intron 25 led to an aberrant fusion transcript in a patient with severe hemophilia A (HA), using comprehensive molecular techniques. This study highlights the value of single-molecule long-read sequencing technologies for molecular diagnosis of HA especially when conventional genetic approaches have failed.

Identifiants

pubmed: 31021037
doi: 10.1111/jth.14460
pii: S1538-7836(22)14363-1
doi:

Substances chimiques

F8 protein, human 839MOZ74GK
Factor VIII 9001-27-8

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

1097-1103

Informations de copyright

© 2019 International Society on Thrombosis and Haemostasis.

Auteurs

Nicolas Chatron (N)

Service de génétique, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
CRNL, équipe GENDEV INSERM U1028, CNRS UMR5292, Université Claude Bernard, Lyon, France.

Caroline Schluth-Bolard (C)

Service de génétique, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
CRNL, équipe GENDEV INSERM U1028, CNRS UMR5292, Université Claude Bernard, Lyon, France.

Mathilde Frétigny (M)

Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.

Audrey Labalme (A)

Service de génétique, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.

Gaëlle Vilchez (G)

Groupe Hospitalier Est, Cellule bioinformatique de la plateforme de séquençage NGS du CHU de Lyon, Bron, France.

Sabine-Marie Castet (SM)

Centre de ressources et compétences-maladies hémorragiques constitutionnelles, Hôpital Universitaire de Bordeaux, Bordeaux, France.

Claude Négrier (C)

Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
EA 4609 Hémostase et cancer, Université Claude Bernard, Lyon, France.

Damien Sanlaville (D)

Service de génétique, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
CRNL, équipe GENDEV INSERM U1028, CNRS UMR5292, Université Claude Bernard, Lyon, France.

Christine Vinciguerra (C)

Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
EA 4609 Hémostase et cancer, Université Claude Bernard, Lyon, France.

Yohann Jourdy (Y)

Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France.
EA 4609 Hémostase et cancer, Université Claude Bernard, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH